DexCom, Inc. (NASDAQ:DXCM) has been given an average recommendation of “Buy” by the twenty-one ratings firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $86.62.

Several research analysts recently issued reports on DXCM shares. BidaskClub raised DexCom from a “hold” rating to a “buy” rating in a research note on Wednesday, June 21st. BTIG Research cut DexCom from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 3rd. William Blair reissued an “outperform” rating on shares of DexCom in a research note on Thursday, April 27th. Jefferies Group LLC dropped their price objective on DexCom to $91.00 and set a “buy” rating on the stock in a research note on Tuesday, May 9th. Finally, Oppenheimer Holdings, Inc. set a $98.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Wednesday, May 3rd.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/18/dexcom-inc-dxcm-receives-consensus-recommendation-of-buy-from-brokerages.html.

In related news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $78.19, for a total value of $113,375.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard Doubleday sold 3,182 shares of the firm’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $68.29, for a total value of $217,298.78. Following the completion of the transaction, the executive vice president now owns 72,395 shares of the company’s stock, valued at approximately $4,943,854.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 33,726 shares of company stock valued at $2,376,466. Company insiders own 1.70% of the company’s stock.

Large investors have recently made changes to their positions in the company. Advisor Group Inc. increased its stake in shares of DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after buying an additional 837 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of DexCom during the first quarter valued at $136,000. IFP Advisors Inc increased its stake in shares of DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock valued at $158,000 after buying an additional 159 shares in the last quarter. Edmond DE Rothschild Holding S.A. bought a new stake in shares of DexCom during the first quarter valued at $164,000. Finally, Mn Services Vermogensbeheer B.V. increased its stake in shares of DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock valued at $179,000 after buying an additional 83 shares in the last quarter.

DexCom (NASDAQ DXCM) opened at 72.78 on Friday. DexCom has a 1-year low of $57.68 and a 1-year high of $96.38. The stock has a 50 day moving average price of $70.65 and a 200-day moving average price of $74.95. The stock’s market cap is $6.30 billion.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The company had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same quarter in the prior year, the firm earned ($0.24) earnings per share. DexCom’s revenue was up 24.3% compared to the same quarter last year. On average, equities analysts expect that DexCom will post ($0.77) EPS for the current year.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.